Shanghai Junshi Bioscience

1877 · HKEX

Public Market Listing

1877HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Junshi Bioscience are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(8 total)
8Total Assets
1Approved
4Phase 3 / Filed
3Phase 1–2 / Early
7Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerBiliary Tract CancerNasopharyngeal Carcinoma
Cholangiocarcinoma
Phase 3
PI3K-alpha (mutant-selective)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
PD-1 + VEGFAMultispecific antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaBreast Cancer
Ongericimab(Junshida)
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Phase 3
IL-17AMonoclonal antibody
Psoriasis
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 2
EGFR + HER3Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
PD-1 (anchoring) / IL-2Rβγ (cis-activation)Protein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
JS207Phase 2Advanced Colorectal Cancer
Est. primary completion 2026-11-27 · NCT06885385 · CT.gov ↗
What to watch
December 2026 (2)
ToripalimabPhase 2/3Hepatocellular Carcinoma
Est. primary completion 2026-12-31 · NCT03859128 · CT.gov ↗
What to watch
ToripalimabPhase 3Advanced Hepatocellular Carcinoma (HCC)
Est. primary completion 2026-12-31 · NCT04523493 · CT.gov ↗
What to watch
2027 (14)
February 2027 (1)
JS105Phase 1/2Advanced Solid Tumors
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
March 2027 (1)
ToripalimabPhase 3Gastric or Esophagogastric Junction Adenocarcinoma
Est. primary completion 2027-03-31 · NCT05180734 · CT.gov ↗
What to watch
April 2027 (1)
JS207Phase 2NSCLC
Est. primary completion 2027-04-30 · NCT06944470 · CT.gov ↗
What to watch
May 2027 (2)
ToripalimabPhase 3Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-05-12 · NCT04848753 · CT.gov ↗
What to watch
ToripalimabPhase 3Intrahepatic Cholangiocarcinoma
Est. primary completion 2027-05-31 · NCT05342194 · CT.gov ↗
What to watch
June 2027 (1)
Toripalimab + JS212Phase 2Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-30 · NCT07484724 · CT.gov ↗
What to watch
July 2027 (1)
ToripalimabPhase 3Limited-stage Small Cell Lung Cancer (LS-SCLC)
Est. primary completion 2027-07-31 · NCT06095583 · CT.gov ↗
What to watch
November 2027 (2)
Toripalimab + JS207 + JS212Phase 2Advanced Lung Cancer
Est. primary completion 2027-11-30 · NCT07309276 · CT.gov ↗
What to watch
Toripalimab + JS207 + JS212Phase 2Advanced Malignant Solid Tumors
Est. primary completion 2027-11-30 · NCT07480733 · CT.gov ↗
What to watch
December 2027 (5)
JS207 + JS212Phase 2Metastatic Colorectal Cancer
Est. primary completion 2027-12-30 · NCT07503756 · CT.gov ↗
What to watch
JS212Phase 1/2Advanced Malignant Solid Tumours
Est. primary completion 2027-12-31 · NCT06888830 · CT.gov ↗
What to watch
JS207Phase 2Non-small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06969027 · CT.gov ↗
What to watch
Toripalimab + JS207 + JS212Phase 2Triple-negative Breast Cancer
Est. primary completion 2027-12-31 · NCT07876557 · CT.gov ↗
What to watch
JS207Phase 2Hepatocellular Carcinoma
Est. primary completion 2027-12-31 · NCT06954467 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
JS207Phase 2Triple-negative Breast Cancer
Est. primary completion 2028-03-22 · NCT07045311 · CT.gov ↗
What to watch
April 2028 (1)
JS111 + JS212Phase 2Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Est. primary completion 2028-04-23 · NCT07518160 · CT.gov ↗
What to watch
July 2028 (1)
JS111Phase 1/2NSCLC
Est. primary completion 2028-07-30 · NCT06940401 · CT.gov ↗
What to watch
2029 (2)
May 2029 (1)
JS105Phase 3Breast Cancer
Est. primary completion 2029-05-31 · NCT07207070 · CT.gov ↗
What to watch
October 2029 (1)
JS207Phase 3Hepatocellular Carcinoma
Est. primary completion 2029-10-30 · NCT07823348 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Filing acceptedToripalimabNMPA accepts sNDA for perioperative toripalimab plus chemotherapy in stage II-III NSCLC
CN, NMPA · Source ↗
5 December 2025Filing acceptedRoconkibartNMPA accepts the roconkibart marketing application in plaque psoriasis
CN, NMPA · Shanghai Junshi Bioscience · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$348M$193M$456M$122Mreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$271M$177M$400M$178Mreport ↗
2023-FY$213M$274M$532M$323Mreport ↗
2022-FY$216M$355M——report ↗